8-K
filed June 16, 2023, 7:59 PM ET
ticker OCUL
CIK 0001393434
other material
confidence high
sentiment neutral
materiality 0.50
Ocular Therapeutix shareholders approve 3.9M share increase under 2021 Stock Incentive Plan
OCULAR THERAPEUTIX, INC
- Approved Amendment No. 2 increasing shares under 2021 Stock Incentive Plan by 3.9M (29.4M for, 8.0M against).
- Elected Jeffrey S. Heier, M.D. and Merilee Raines as Class III directors until 2026 annual meeting.
- Ratified PricewaterhouseCoopers as independent auditor for FY 2023 (60.5M for, 43K against).
- Non-binding advisory vote on named executive officer compensation passed (26.5M for, 11.2M against).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
OCULAR THERAPEUTIX, INC shareholders approved Election of Class III directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
The Company’s stockholders elected Jeffrey S. Heier, M.D. and Merilee Raines as Class III directors to serve until the 2026 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory proposal regarding compensation of named executive officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved a non-binding, advisory proposal regarding the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
OCULAR THERAPEUTIX, INC shareholders approved Amendment No. 2 to increase shares under the 2021 Stock Incentive Plan by 3,900,000 shares.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved Amendment No. 2 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 3,900,000 shares.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
OCULAR THERAPEUTIX, INC shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-31
Exact text from the filing
The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.